Analysis of breast cancer subtypes indicated that the expression of DLC1, DLC2, and DLC3 was significantly lower in triple-negative breast cancer (TNBC) than in the other subtypes (Figure S1). Here, STARD13 is linked to triple-negative breast carcinoma.